Small molecule-based PD-1 pathway blockade for Human cancer therapy: Linagliptin (brand name: BI-1356/Tradjenta), an inhibitor of dipeptidylpeptidase-4 (DPP-4), increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 3/January/2017, 5.12 pm

Cardiac rejuvenation therapy: AML-3 (Cbfa1/Runx2) suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy and heart failure via up regulation of its target gene, 3/January/2017, 2.09 pm
January 3, 2017
Anti-telomerase cancer therapy: MiR-601 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of it target gene, 3/January/2017, 7.25 pm
January 3, 2017
Show all

Introduction:What they say

A recent study from Cell Signalling Section, Division of Immunology, Department of Pathology, Tennis Court Road, University of Cambridge, Cambridge CB2 1QP, UK shows that “Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses.” This study was published in the 16 February 2016 issue of Immunity (one of the best journals in Immunology with an impact factor of 20+) by Prof Rudd CE, Taylor A and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule-based PD-1 pathway blockade for Human cancer therapy:  Linagliptin,  an inhibitor of dipeptidylpeptidase-4 (DPP-4),  increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene


What is known?

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year a few years ago.


Research Findings

This study suggests a small molecule-based Human cancer immunotherapy. Linagliptin (known by its trade names, such as BI-1356/Tradjenta) is used in the treatment of TIIDM.

price-50[easy_payment currency=”USD”]

The study presented here suggests that, Linagliptin, by decreasing the expression of its target gene, it may: (a) increase transcription factor T-bet expression; (b) inhibit co-inhibitory receptor PD-1 expression;  (c) increase CD8(+) cytotoxic T lymphocyte function; (d) augment anti-tumor activity; & (e) inhibit metastatic cancer progression.


Therapeutic opportunity

Thus, pharmacological formulations encompassing “Linagliptin or its analogues or Linagliptin plus any of the known anti-cancer agents” may be used to inhibit the progression of tumors.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $50

Undisclosed mechanistic information: How Linagliptin suppresses the expression of PD-1 and augments anti-tumor immunity

# Research cooperation


References:

Citation: Boominathan, L., Small molecule-based PD-1 pathway blockade for Human cancer therapy:  Linagliptin (brand name: BI-1356/Tradjenta),  an inhibitor of dipeptidylpeptidase-4 (DPP-4),  increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 3/January/2017, 5.12 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.